director
48,065 · $10.55 · $507.01K
ALMS는 ALUMIS INC.의 미국 주식 종목코드입니다.
2026-09-13 데이터 기준: 현재가 $9.18, 시가총액 $1.16B, 최근 13F 기관 변화 12건.
Yahoo Finance ↗·갱신 2026. 09. 13. 오전 05:00 UTC
Yahoo Finance
SEC EDGAR weighted-average basic shares × Yahoo Finance price
SEC EDGAR
earnings
자료 없음
| 날짜 | 거래자 / 직책 | 거래 | 수량 | 평균 단가 | 거래 금액 | 출처 |
|---|---|---|---|---|---|---|
| 2026. 09. 08. | AKKARAJU SRINIVAS director | 매도 | 48,065 | $10.55 | $507.01K | SEC ↗ |
| 2026. 09. 08. | AKKARAJU SRINIVAS director | 매수 | 273,291 | $10.63 | $2.9M | SEC ↗ |
| 2026. 09. 08. | AKKARAJU SRINIVAS director | 매수 | 273,290 | $10.63 | $2.9M | SEC ↗ |
| 2026. 09. 08. | AKKARAJU SRINIVAS director | 매도 | 48,066 | $10.55 | $507.02K | SEC ↗ |
| 2026. 09. 04. | AKKARAJU SRINIVAS director | 매수 | 220,070 | $11.17 | $2.46M | SEC ↗ |
| 2026. 09. 04. | AKKARAJU SRINIVAS director | 매수 | 220,070 | $11.17 | $2.46M | SEC ↗ |
| 2026. 08. 03. | Bradley Mark Christopher Chief Development Officer | 매도 | 2,572 | $26.37 | $67.82K | SEC ↗ |
| 2026. 08. 03. | Hardiman Roy C. Chief Business & Strategy Ofcr | 매도 | 2,692 | $26.37 | $70.99K | SEC ↗ |
| 2026. 08. 03. | Schroer John R. Chief Financial Officer | 매도 | 3,282 | $26.37 | $86.55K | SEC ↗ |
| 2026. 08. 03. | Goldstein David M Chief Scientific Officer | 매도 | 2,596 | $26.37 | $68.46K | SEC ↗ |
| 2026. 08. 03. | Drappa Jorn Chief Medical Officer | 매도 | 2,447 | $26.37 | $64.53K | SEC ↗ |
| 2026. 08. 03. | Pangali Sanam Chief Legal Officer | 매도 | 1,364 | $26.37 | $35.97K | SEC ↗ |
director
48,065 · $10.55 · $507.01K
director
273,291 · $10.63 · $2.9M
director
273,290 · $10.63 · $2.9M
director
48,066 · $10.55 · $507.02K
director
220,070 · $11.17 · $2.46M
director
220,070 · $11.17 · $2.46M
Chief Development Officer
2,572 · $26.37 · $67.82K
Chief Business & Strategy Ofcr
2,692 · $26.37 · $70.99K
Chief Financial Officer
3,282 · $26.37 · $86.55K
Chief Scientific Officer
2,596 · $26.37 · $68.46K
Chief Medical Officer
2,447 · $26.37 · $64.53K
Chief Legal Officer
1,364 · $26.37 · $35.97K
갱신: 2026. 09. 10. 오전 05:35 UTC
| 기준 분기 | 기관명 | 거래 | 보유 수량 | 수량 변화 | 금액 변화 | 출처 |
|---|---|---|---|---|---|---|
| 2026. 06. 30. | BlackRock, Inc. | 추가 매수 | 8,218,151 | +1,047,283 | +$73.28M | SEC 13F ↗ |
| 2026. 06. 30. | FMR LLC / Fidelity | 추가 매수 | 6,769,170 | +5,795,388 | +$169.03M | SEC 13F ↗ |
| 2026. 06. 30. | Vanguard Capital Management LLC | 추가 매수 | 4,215,703 | +183,437 | +$29.8M | SEC 13F ↗ |
| 2026. 03. 31. | UBS Group AG | 추가 매수 | 3,054,865 | +2,940,869 | +$64.79M | SEC 13F ↗ |
| 2026. 06. 30. | State Street Corp | 추가 매수 | 2,187,266 | +385,454 | +$21.86M | SEC 13F ↗ |
| 2026. 06. 30. | Geode Capital Management, LLC | 추가 매수 | 2,168,517 | +250,102 | +$18.76M | SEC 13F ↗ |
| 2026. 03. 31. | Janus Henderson Group PLC | 추가 매수 | 2,124,408 | +29,331 | +$646.02K | SEC 13F ↗ |
| 2026. 03. 31. | Invesco Ltd. | 추가 매수 | 1,511,537 | +1,089,673 | +$24.01M | SEC 13F ↗ |
| 2026. 06. 30. | JPMorgan Chase & Co. | 신규 매수 | 969,617 | +108,042 | +$8.99M | SEC 13F ↗ |
| 2026. 06. 30. | Vanguard Portfolio Management LLC | 추가 매수 | 921,211 | +208,603 | +$10.22M | SEC 13F ↗ |
| 2026. 03. 31. | Marshall Wace, LLP | 추가 매수 | 1,172,749 | +799,856 | +$17.62M | SEC 13F ↗ |
| 2026. 03. 31. | Goldman Sachs Group Inc. | 추가 매수 | 718,040 | +290,889 | +$6.41M | SEC 13F ↗ |
보유 수량은 공시 보유금액을 해당 공시의 종목 단가로 나눈 값이며 반올림 표시합니다.
번역 없음 · 원문 표시
Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise
ALUMIS INC. (ALMS)번역 없음 · 원문 표시
Alumis delivered a focused and productive first quarter, building on the Phase 3 clinical validation of envudeucitinib in moderate - to - severe plaque psoriasis and reinforcing the differentiated potential of maximal TYK2 inhibition
ALUMIS INC. (ALMS)가격은 Yahoo Finance, 실적 발표일은 Nasdaq, 회사 기초정보는 Polygon.io를 우선 사용합니다. Polygon 시가총액을 받을 수 없으면 SEC의 최근 발행주식 수에 Yahoo 현재가를 곱한 값을 계산값으로 표시합니다. 내부자·기관 거래는 SEC EDGAR 원문을 기준으로 하며 누락값은 임의 생성하지 않습니다.
갱신: 2026. 09. 13. 오전 05:00 UTC
수집·계산·정정 원칙